Name | Alemtuzumab |
---|
Description | Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52, a glycoprotein expressed on the surface of most lymphoid, and to a lesser extent, myeloid cell types. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes[1][2]. |
---|---|
Related Catalog | |
References |
No Any Chemical & Physical Properties |